Search

Your search keyword '"Spacal, B."' showing total 1 results
Start Over Author "Spacal, B." Topic desensitization, immunologic

Refine your results

1 results on '"Spacal, B."'

1. Safety of ultrashort-term sit with pollen allergoids adjuvanted by monophosphoryl lipid A: a prospective Italian survey.

Author

Crivellaro M, Senna GE, Pappacoda A, Vanzelli R, Spacal B, Marchi G, Recchia G, and Makatsori M

Subjects
Adult, Allergoids, Female, Humans, Italy, Lipid A administration & dosage, Male, Middle Aged, Prospective Studies, Adjuvants, Immunologic administration & dosage, Desensitization, Immunologic adverse effects, Lipid A analogs & derivatives, Plant Extracts adverse effects
Abstract

A 3-year prospective post marketing survey on the safety of the recently developed ultrashort pre-seasonal subcutaneous immunotherapy (uSCIT-MPL4) with pollen allergoids adjuvanted with monophosphoryl lipid A was performed. A total of 510 patients received uSCIT-MPL4, 61% for grass, 35.7% for birch, 13.2% for parietaria and 3% for other pollens (ragweed, mugwort, and olive). A total of 3308 injections were given and the mean duration of uSCIT-MPL-4 was 2.3 years. Overall, only 7 slight systemic reactions (SR) were observed in 510 patients (1.37%) and 2.11/1000 injections suggesting that this treatment is even safer than traditional depot injection SIT.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results